vs
Side-by-side financial comparison of Becton Dickinson (BDX) and Sherwin-Williams (SHW). Click either name above to swap in a different company.
Sherwin-Williams is the larger business by last-quarter revenue ($5.7B vs $5.3B, roughly 1.1× Becton Dickinson). Sherwin-Williams runs the higher net margin — 9.4% vs 7.3%, a 2.2% gap on every dollar of revenue. On growth, Sherwin-Williams posted the faster year-over-year revenue change (6.8% vs -0.4%). Over the past eight quarters, Becton Dickinson's revenue compounded faster (2.0% CAGR vs -4.9%).
Becton, Dickinson and Company is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain areas.
Sherwin-Williams is an American paints and coatings company based in Cleveland, Ohio. It is primarily engaged in the manufacture, distribution, and sale of paints, coatings, floorcoverings, and related products with operations in over 120 countries. As of 2024, it is the largest coatings company in the world by revenue.
BDX vs SHW — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $5.3B | $5.7B |
| Net Profit | $382.0M | $534.7M |
| Gross Margin | 45.9% | 49.1% |
| Operating Margin | 10.5% | — |
| Net Margin | 7.3% | 9.4% |
| Revenue YoY | -0.4% | 6.8% |
| Net Profit YoY | 24.0% | 6.1% |
| EPS (diluted) | $1.34 | $2.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $5.7B | ||
| Q4 25 | $5.3B | $5.6B | ||
| Q3 25 | $5.9B | $6.4B | ||
| Q2 25 | $5.5B | $6.3B | ||
| Q1 25 | $5.3B | $5.3B | ||
| Q4 24 | $5.2B | $5.3B | ||
| Q3 24 | $5.4B | $6.2B | ||
| Q2 24 | $5.0B | $6.3B |
| Q1 26 | — | $534.7M | ||
| Q4 25 | $382.0M | $476.8M | ||
| Q3 25 | $493.0M | $833.1M | ||
| Q2 25 | $574.0M | $754.7M | ||
| Q1 25 | $308.0M | $503.9M | ||
| Q4 24 | $303.0M | $480.1M | ||
| Q3 24 | $400.0M | $806.2M | ||
| Q2 24 | $487.0M | $889.9M |
| Q1 26 | — | 49.1% | ||
| Q4 25 | 45.9% | 48.5% | ||
| Q3 25 | 47.5% | 49.2% | ||
| Q2 25 | 47.8% | 49.4% | ||
| Q1 25 | 42.8% | 48.2% | ||
| Q4 24 | 43.2% | 48.6% | ||
| Q3 24 | 45.7% | 49.1% | ||
| Q2 24 | 46.2% | 48.8% |
| Q1 26 | — | — | ||
| Q4 25 | 10.5% | 11.4% | ||
| Q3 25 | 11.8% | 16.7% | ||
| Q2 25 | 16.0% | 15.6% | ||
| Q1 25 | 10.4% | 12.3% | ||
| Q4 24 | 8.8% | 11.6% | ||
| Q3 24 | 11.4% | 21.4% | ||
| Q2 24 | 12.1% | 22.5% |
| Q1 26 | — | 9.4% | ||
| Q4 25 | 7.3% | 8.5% | ||
| Q3 25 | 8.4% | 13.1% | ||
| Q2 25 | 10.4% | 12.0% | ||
| Q1 25 | 5.8% | 9.5% | ||
| Q4 24 | 5.9% | 9.1% | ||
| Q3 24 | 7.4% | 13.1% | ||
| Q2 24 | 9.8% | 14.2% |
| Q1 26 | — | $2.15 | ||
| Q4 25 | $1.34 | $1.91 | ||
| Q3 25 | $1.71 | $3.35 | ||
| Q2 25 | $2.00 | $3.00 | ||
| Q1 25 | $1.07 | $2.00 | ||
| Q4 24 | $1.04 | $1.90 | ||
| Q3 24 | $1.37 | $3.18 | ||
| Q2 24 | $1.68 | $3.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $740.0M | $216.9M |
| Total DebtLower is stronger | — | $11.7B |
| Stockholders' EquityBook value | $25.3B | $4.4B |
| Total Assets | $54.8B | $26.4B |
| Debt / EquityLower = less leverage | — | 2.64× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $216.9M | ||
| Q4 25 | $740.0M | $207.2M | ||
| Q3 25 | $641.0M | $241.5M | ||
| Q2 25 | $735.0M | $269.8M | ||
| Q1 25 | $667.0M | $199.8M | ||
| Q4 24 | $711.0M | $210.4M | ||
| Q3 24 | $1.7B | $238.2M | ||
| Q2 24 | $4.5B | $200.0M |
| Q1 26 | — | $11.7B | ||
| Q4 25 | — | $9.7B | ||
| Q3 25 | — | $9.7B | ||
| Q2 25 | — | $9.0B | ||
| Q1 25 | — | $9.0B | ||
| Q4 24 | — | $9.2B | ||
| Q3 24 | — | $9.2B | ||
| Q2 24 | — | $9.0B |
| Q1 26 | — | $4.4B | ||
| Q4 25 | $25.3B | $4.6B | ||
| Q3 25 | $25.4B | $4.4B | ||
| Q2 25 | $25.5B | $4.4B | ||
| Q1 25 | $25.2B | $4.1B | ||
| Q4 24 | $25.2B | $4.1B | ||
| Q3 24 | $25.9B | $4.2B | ||
| Q2 24 | $25.9B | $3.8B |
| Q1 26 | — | $26.4B | ||
| Q4 25 | $54.8B | $25.9B | ||
| Q3 25 | $55.3B | $26.2B | ||
| Q2 25 | $54.9B | $25.4B | ||
| Q1 25 | $54.5B | $24.6B | ||
| Q4 24 | $54.7B | $23.6B | ||
| Q3 24 | $57.3B | $24.0B | ||
| Q2 24 | $55.6B | $23.7B |
| Q1 26 | — | 2.64× | ||
| Q4 25 | — | 2.10× | ||
| Q3 25 | — | 2.18× | ||
| Q2 25 | — | 2.04× | ||
| Q1 25 | — | 2.17× | ||
| Q4 24 | — | 2.28× | ||
| Q3 24 | — | 2.22× | ||
| Q2 24 | — | 2.39× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $657.0M | — |
| Free Cash FlowOCF − Capex | $549.0M | — |
| FCF MarginFCF / Revenue | 10.5% | — |
| Capex IntensityCapex / Revenue | 2.1% | 2.4% |
| Cash ConversionOCF / Net Profit | 1.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.6B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $657.0M | $1.1B | ||
| Q3 25 | $1.4B | $1.3B | ||
| Q2 25 | $1.2B | $1.1B | ||
| Q1 25 | $164.0M | $-61.1M | ||
| Q4 24 | $693.0M | $934.5M | ||
| Q3 24 | $1.2B | $1.1B | ||
| Q2 24 | $1.3B | $1.2B |
| Q1 26 | — | — | ||
| Q4 25 | $549.0M | $862.1M | ||
| Q3 25 | $1.0B | $1.1B | ||
| Q2 25 | $1.0B | $931.1M | ||
| Q1 25 | $35.0M | $-250.4M | ||
| Q4 24 | $588.0M | $634.5M | ||
| Q3 24 | $882.0M | $839.4M | ||
| Q2 24 | $1.1B | $952.0M |
| Q1 26 | — | — | ||
| Q4 25 | 10.5% | 15.4% | ||
| Q3 25 | 17.0% | 17.5% | ||
| Q2 25 | 19.0% | 14.7% | ||
| Q1 25 | 0.7% | -4.7% | ||
| Q4 24 | 11.4% | 12.0% | ||
| Q3 24 | 16.2% | 13.6% | ||
| Q2 24 | 22.4% | 15.2% |
| Q1 26 | — | 2.4% | ||
| Q4 25 | 2.1% | 4.1% | ||
| Q3 25 | 6.0% | 3.1% | ||
| Q2 25 | 3.2% | 2.9% | ||
| Q1 25 | 2.4% | 3.6% | ||
| Q4 24 | 2.0% | 5.7% | ||
| Q3 24 | 5.4% | 3.8% | ||
| Q2 24 | 3.6% | 4.0% |
| Q1 26 | — | — | ||
| Q4 25 | 1.72× | 2.29× | ||
| Q3 25 | 2.75× | 1.57× | ||
| Q2 25 | 2.12× | 1.47× | ||
| Q1 25 | 0.53× | -0.12× | ||
| Q4 24 | 2.29× | 1.95× | ||
| Q3 24 | 2.94× | 1.33× | ||
| Q2 24 | 2.66× | 1.35× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
SHW
Segment breakdown not available.
